EORTC 1702-LCG-ROG Targeted therapy with or without dose-intensified radiotterapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors
| abstract |
Targeted therapy beyond Progression with or without dose-intensified radiotHerapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors (HALT) Objectives: To determine wether in patients with Mutation positive advanced NSCLC the use of SBRT to ≤ 3 sites of OPD with continuation of TKI improves Progression free survival (PFS) compared with continuation of TKI alone. Target: 110 Patients for Phase II component |
| type of project | clinical studies |
| status | ongoing - recruiting phase |
| start of project | 2019 |
| end of project | 2025 |
| study design | Multicenter, Randomized Phase II / III Trial |
| responsible person | Dr. Markus Glatzer |